Plasma phosphorylated tau181 outperforms [ 18F ] fluorodeoxyglucose positron emission tomography in the identification of early Alzheimer disease
Year: 2024
Type: article
Abstract: Background and purpose This study was undertaken to compare the performance of plasma p‐tau181 with that of [18F]fluorodeoxyglucose (FDG) positron emission tomography (PET) in the identification of early biological Alzheimer disease (AD). Methods We included 533 cognitively impaired participants from the Alzheimer's Disease Neuroimaging Initiative. Participants underwent PET scans, biofluid collection, and cognitive tests. Receiver operating characteristic analyses were used to determine the diagnostic accuracy of plasma p‐tau181 and [18F]FDG‐PET using clinical diagnosis and core AD biomarkers ([18F]florbetapir‐PET and cerebrospinal fluid [CSF] p‐tau181) as reference standards. Differences in the diagnostic accuracy between plasma p‐tau181 and [18F]FDG‐PET were determined by bootstrap‐based tests. Correlations of [18F]FDG‐PET and plasma p‐tau181 with CSF p‐tau181, amyloid β (Aβ) PET, and cognitive performance were evaluated to compare associations between measurements. Results We observed that both plasma p‐tau181 and [18F]FDG‐PET identified individuals with positive AD biomarkers in CSF or on Aβ‐PET. In the MCI group, plasma p‐tau181 outperformed [18F]FDG‐PET in identifying AD measured by CSF (p = 0.0007) and by Aβ‐PET (p = 0.001). We also observed that both plasma p‐tau181 and [18F]FDG‐PET metabolism were associated with core AD biomarkers. However, [18F]FDG‐PET uptake was more closely associated with cognitive outcomes (Montreal Cognitive Assessment, Mini‐Mental State Examination, Clinical Dementia Rating Sum of Boxes, and logical memory delayed recall, p < 0.001) than plasma p‐tau181. Conclusions Overall, although both plasma p‐tau181 and [18F]FDG‐PET were associated with core AD biomarkers, plasma p‐tau181 outperformed [18F]FDG‐PET in identifying individuals with early AD pathophysiology. Taken together, our study suggests that plasma p‐tau181 may aid in detecting individuals with underlying early AD.
Source: European Journal of Neurology
DOI: 10.1111/ene.16255
Authors: Kely Monica Quispialaya, Joseph Therriault, Antonio Aliaga, Cécile Tissot, Stijn Servaes, Nesrine Rahmouni, Thomas K. Karikari, Andrea L. Benedet, Nicholas J. Ashton, Arthur C. Macedo, Firoza Z. Lussier, Jenna Stevenson, Yi‐Ting Wang, Jaime Fernandez Arias, Ali Hosseini, Takashi Matsudaira, Bertrand Jean‐Claude, Brian M. Gilfix, Eduardo R. Zimmer, Jean‐Paul Soucy, Tharick A. Pascoal, Serge Gauthier, Henrik Zetterberg, Kaj Blennow, Pedro Rosa‐Neto, for the Alzheimer's Disease Neuroimaging Initiative
Institutions: Montreal Neurological Institute and Hospital, Douglas Mental Health University Institute, McGill University Research Centre for Studies in Aging, McGill University, Universidade Federal do Rio Grande do Sul, University of Pittsburgh, University of Gothenburg, Wallenberg Centre for Molecular and Translational Medicine, Hamamatsu University, Hamamatsu University School of Medicine, National Epilepsy Center, National Hospital Organization, Instituto do Cérebro, Pontifícia Universidade Católica do Rio Grande do Sul, Sahlgrenska University Hospital, UK Dementia Research Institute, UCL Queen Square Institute of Neurology, University College London
Language: English
Subfield: Psychiatry and Mental health
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,600
Funders: U.S. Department of Defense, Alzheimer's Association, Bristol-Myers Squibb, Eli Lilly and Company, Biogen, University of Southern California, F. Hoffmann-La Roche, Alzheimer's Disease Neuroimaging Initiative, Familjen Erling-Perssons Stiftelse, BioClinica, McGill University, Fondation Brain Canada, Northern California Institute for Research and Education, Stiftelsen för Gamla Tjänarinnor, Weston Brain Institute, EU Joint Programme – Neurodegenerative Disease Research, Consortium canadien en neurodégénérescence associée au vieillissement, National Institute for Health and Care Research, University College London, European Commission, Eisai, Hjärnfonden, Vetenskapsrådet, UK Dementia Research Institute, National Institutes of Health, Genentech, University of California, San Diego, HORIZON EUROPE Framework Programme, Canadian Institutes of Health Research, Fonds de Recherche du Québec - Santé, Japan Society for the Promotion of Science, National Institute on Aging
Awards: G1012222616, G1088883541, G150733400, G1554142629, G1625201577, G1650819308, G1673988714, G1802301745, G1833008592, G2104733190, G2152643862, G2189010064, G2308068485, G2340207221, G235135605, G2423217232, G2423387114, G2522063444, G2543812357, G2835601961, G29951154, G311122596, G3131374986, G3167845995, G3216574877, Fluid biomarkers for neurodegenerative dementias, In vivo quantification of biomarker progression on the APP-RAT model, G3553156159, G3710456697, G3870774570, G3908963977, G3914690605, G3966393351, G4119534169, G4260843567, G43180419, G432431387, G434337789, G4377393254, G4475667458, G4729658625, G4800177743, G499080294, G5040492720, G506008078, G516766298, G5207404921, G528601746, G5365730499, EFFECTS OF TRAUMATIC BRAIN INJURY (TBI) AND POST TRAUMATIC STRESS DISORDER (PTSD) ON ALZHEIMER'S DISEASE (AD) IN VETERANS USING IMAGING AND BIOMARKERS IN THE AD NEUROIMAGING INITIATIVE (ADNI)", G5544413620, G5654639750, Alzheimer's Disease Neuroimaging Initiative, G5813287008, G5850682332, G5880387862, G5901863754, G6039058924, CASCADE: CAuSe or Consequence in Alzheimer DiseasE?, G6158734006, G6210868510, G6236917951, G6371410416, G639136054, G6412110892, G6522198425, G6532618440, Multi-omics Interdisciplinary Research Integration to Address DEmentia diagnosis, G6745400708, G6792506723, G6899163935, G6948409098, G7077458143, G7154687859, G72415811, G764699806, G7764010130, G781725486, In vivo imaging for mitochondrial dysfunction and neuroinflammation in refractory temporal lobe epilepsy, G8228018387, G8263961129, G8895907669, G8897063270, G8957659042, G9000122335, Arizona Alzheimer's Disease Research Center, Plasma brain-derived tau: a novel Alzheimer’s disease-type neurodegeneration biomarker with potential to complete the AT(N) scheme in blood, G915560672
OpenAlex ID: W4403716428